Last Price$2.95.0%
Market Cap$2,541.3M
LTM Net Debt
($1,148.5M)
YoY Growth
N/A
3Y CAGR
N/A
5Y CAGR
N/A
Stock quality & Intrinsic value
5/10
11,448.4% undervalued
Heart Test Laboratories, Inc. Net Debt
Annual
Quarterly
LTM
Crunching data... Almost there!
| Apr'20 | Apr'21 | Apr'22 | Apr'23 | Apr'24 | |
|---|---|---|---|---|---|
| Net Debt | $445.9K | $2,355.3K | $5,244.5K | ($94.6K) | ($4,771.3K) |
Overvalued or undervalued?
Check the intrinsic value for HSCS
and see if it's the right time to invest.
Heart Test Laboratories, Inc. (HSCS) Net Debt comparison analysis
General
LTM Net Debt
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Heart Test Laboratories, Inc.HSCS
($1,148.5M)
N/A
N/A
N/A
Median Peer Set
$5,550.5M
(6.0%)
(1.2%)
2.9%
Medtronic plcMDT
$18.7B
10.8%
10.3%
4.5%
Boston Scientific CorporationBSX
$10.7B
24.4%
12.5%
1.3%
Stryker CorporationSYK
$9,195.0M
(11.9%)
(2.4%)
5.5%
Abbott LaboratoriesABT
$7,054.0M
(15.5%)
(7.8%)
(14.0%)
Zimmer Biomet Holdings, Inc.ZBH
$5,679.1M
1.2%
(5.3%)
(6.3%)
Koninklijke Philips N.V.PHG
$5,421.8M
(14.4%)
3.9%
5.4%
STERIS plcSTE
$2,132.3M
(35.6%)
(12.1%)
15.0%
DexCom, Inc.DXCM
($50.5M)
(61.2%)
(55.5%)
(33.0%)
Insulet CorporationPODD
($869.6M)
N/A
N/A
N/A
Edwards Lifesciences CorporationEW
($3,275.9M)
254.3%
61.6%
31.3%
HSCS key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Apr'20 | Apr'21 | Apr'22 | Apr'23 | Apr'24 | |
|---|---|---|---|---|---|
% growth | 0.1 0.0% | 0.0 (60.1%) | 0.0 (43.9%) | 0.0 (64.2%) | 0.0 261.2% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
% margin | 0.0 27.6% | 0.0 58.3% | 0.0 45.1% | 0.0 45.7% | 0.0 67.3% |
| Operating Expenses | 3.8 | 2.6 | 4.7 | 6.1 | 6.3 |
| Research & Development Expenses (R&D) | 2.0 | 1.7 | 3.0 | 2.5 | 2.9 |
| Selling, General & Administrative Expenses (SG&A) | 1.8 | 0.9 | 1.7 | 3.7 | 3.4 |
% margin | (3.8) (5,949.0%) | (2.6) (10,030.2%) | (4.7) (32,765.6%) | (6.1) (118,698.3%) | (6.3) (33,902.0%) |
| Interest Income | 0.0 | 0.1 | 0.4 | 0.2 | 0.0 |
| Interest Expense | 0.0 | 0.1 | 0.4 | 0.2 | 0.4 |
| Pre-tax Income | (3.8) | (2.5) | (4.8) | (6.4) | (6.6) |
% effective tax rate | 0.0 (0.6%) | 0.1 (5.3%) | (0.3) 5.2% | 484.5 (7,624.8%) | 0.0 0.0% |
% margin | (3.8) (5,973.4%) | (2.6) (10,081.1%) | (4.6) (31,851.8%) | (490.9) (9,531,151.3%) | (6.6) (35,511.9%) |
| EPS | (115.69) | (77.89) | (137.94) | (6,173.88) | (18.74) |
| Diluted EPS | (115.69) | (77.89) | (137.94) | (6,173.88) | (18.74) |
% margin | (3.7) (5,834.2%) | (2.3) (8,928.7%) | (4.4) (30,822.2%) | (6.1) (118,139.8%) | (6.2) (33,096.7%) |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Heart Test Laboratories, Inc.'s Net Debt?
As of today, Heart Test Laboratories, Inc.'s last 12-month Net Debt is ($1,148.5M), based on the financial report for Oct 31, 2024 (Q4’2024).
2) What is Heart Test Laboratories, Inc.'s Net Debt growth rate?
Over the last year, Heart Test Laboratories, Inc.'s Net Debt growth was N/A. The average annual Net Debt growth rates for Heart Test Laboratories, Inc. have been N/A over the past three years, N/A over the past five years.